Compare Incyte Corporation (INCY) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Suncor Energy Inc. — how do they compare? Incyte Corporation trades at $120.62 (market cap $24.54B), while Suncor Energy Inc. trades at $63.65 (market cap $74.07B). The key difference: Suncor Energy Inc. is far larger — about 3× Incyte Corporation's market cap, and Suncor Energy Inc. pays a 2.7% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SU | |
|---|---|---|
Market Cap | $24.54B | $74.07B |
Sector | Health | Energy |
52-Week High | $129.93 | $69.73 |
52-Week Low | $81.61 | $38.17 |
Enterprise Value | $20.04B | $80.75B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Suncor Energy (SU) trades at $62.73, up 4.38% today, with a bearish technical signal but strong fundamentals including a P/E of 11.79 and net margin of 14.7%. Recent Q2 2026 earnings beat estimates at $2.27 EPS, driven by higher crude realizations and refining margins (Reuters, 2026-08-04). The company maintains a consistent dividend of $0.60 per share and announced a CEO transition to Peter Zebedee in 2027.
Outlook is supported by solid cash flow and buybacks, but risks include commodity price volatility and operational disruptions. Analyst consensus is strongly bullish with 74% buy ratings, targeting upside from efficient operations and debt reduction, though technical weakness near support at $61 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
